Status:
TERMINATED
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
Amyloidosis
Leukocyte Chemotactic Factor 2 Amyloidosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be en...
Detailed Description
Refer to www.studyALECT2.com
Eligibility Criteria
Inclusion
- Males and females, age 18 years or older;
- Renal biopsy-proven diagnosis of ALECT2;
- For patients with kidney disease that could be due to ALECT2, a renal biopsy may be obtained to confirm ALECT2 diagnosis.
Exclusion
- \- There are no exclusion criteria for this observational study.
Key Trial Info
Start Date :
January 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 18 2020
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03774784
Start Date
January 29 2019
End Date
May 18 2020
Last Update
June 16 2020
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
Scottsdale, Arizona, United States, 85259
2
Clinical Trial Site
Tucson, Arizona, United States, 85724
3
Clinical Trial Site
Denver, Colorado, United States, 80210
4
Clinical Trial Site
Chicago, Illinois, United States, 60611